Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity

Open access

Abstract

Cellular senescence is a state of stable growth arrest and a desired outcome of tumor suppressive interventions. Treatment with many anti-cancer drugs can cause premature senescence of non-malignant cells. These therapy-induced senescent cells can have pro-tumorigenic and pro-disease functions via activation of an inflammatory secretory phenotype (SASP). Inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i) have recently proven to restrain tumor growth by activating a senescence-like program in cancer cells. However, the physiological consequence of exposing the whole organism to pharmacological CDK4/6i remains poorly characterized. Here, we show that exposure to CDK4/6i induces non-malignant cells to enter a premature state of senescence dependent on p53. We observe in mice and breast cancer patients that the CDK4/6i-induced senescent program activates only a partial SASP enriched in p53 targets but lacking pro-inflammatory and NF-κB-driven components. We find that CDK4/6i-induced senescent cells do not acquire pro-tumorigenic and detrimental properties but retain the ability to promote paracrine senescence and undergo clearance. Our results demonstrate that SASP composition is exquisitely stress-dependent and a predictor for the biological functions of different senescence subsets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/embj.2021108946

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure EV1 Prolonged CDK4/6i treatment induces p53‐dependent cellular senescence A–CHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 1 or 8 times in 24 h). Protein was isolated from vehicle or abemaciclib‐treated cells and immunoblotted for p‐Rb, Rb, and actin (A). RNA was isolated from treated cells, and mRNA levels of E2F2 gene (B) and p16 gene (C) were quantified by qPCR relative to tubulin (internal control). n = 3 independent experiments.D–F8‐day population doubling of WI38 cells treated with vehicle, palbociclib, or abemaciclib (both 1 μM for 8 times in 24 h; n = 3 independent experiments) (D). At 8 dpt, treated WI38 cells were incubated with EdU for 10 h and stained (scale bar, 150 μm; n = 6 samples from 3 independent experiments) (E). 3 × 103 treated WI38 cells were replated in 6‐well dish, cultured for 8 days, and stained with 0.2% crystal violet (n = 3 independent experiments) (F).G, HCells were treated with vehicle or abemaciclib (1 μM for 1 or 4 or 8 times in 24 h), after drug withdraw, either replated for colony formation assay (n = 3 independent experiments) (G) or incubated with EdU for 10 h, and stained at 8 dpt (n = 9 samples from 3 independent experiments) (H).ICells were treated with vehicle or abemaciclib (250 nM or 500 nM or 1 μM for 8 times in 24 h); after drug withdraw, the cells were replated for colony formation assay (n = 3 independent experiments).JRepresentative phase‐contrast images of BJ or WI38 cells at the end of each drug treatment (scale bar, 1 mm; n = 3 independent experiments).KAt 8 dpt, treated BJ cells were fixed and stained for SA‐β‐gal and quantified (scale bar, 1 mm; n = 3 independent experiments).LWhole‐cell lysate of treated BJ cells was used to immunoblot for p16 (n = 3 independent experiments).M–ORNA‐sequencing was performed with human fibroblasts (BJ) treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h) (n = 3 independent samples, sequenced together). Heatmap of cell cycle genes (M), senescence signature (N), and p53‐repressed (red) and p53‐activated (blue) cell cycle‐related genes (O) calculated from RNA‐seq datasets of cells 8 dpt relative to the vehicle‐treated group.PCells were treated with vehicle or abemaciclib (1 μM for 8 times in 24 h); after drug withdraw, the nuclear fraction was isolated and protein extracted for Western blotting. Lamin A/C was used as the marker of nucleus and loading control (n = 3 independent experiments). Data information: Data are means ± SD. Two‐way ANOVA (B, C, and H). One‐way ANOVA (D, E, and K). ***P < 0.001.
Figure EV1 Prolonged CDK4/6i treatment induces p53‐dependent cellular senescence A–CHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 1 or 8 times in 24 h). Protein was isolated from vehicle or abemaciclib‐treated cells and immunoblotted for p‐Rb, Rb, and actin (A). RNA was isolated from treated cells, and mRNA levels of E2F2 gene (B) and p16 gene (C) were quantified by qPCR relative to tubulin (internal control). n = 3 independent experiments.D–F8‐day population doubling of WI38 cells treated with vehicle, palbociclib, or abemaciclib (both 1 μM for 8 times in 24 h; n = 3 independent experiments) (D). At 8 dpt, treated WI38 cells were incubated with EdU for 10 h and stained (scale bar, 150 μm; n = 6 samples from 3 independent experiments) (E). 3 × 103 treated WI38 cells were replated in 6‐well dish, cultured for 8 days, and stained with 0.2% crystal violet (n = 3 independent experiments) (F).G, HCells were treated with vehicle or abemaciclib (1 μM for 1 or 4 or 8 times in 24 h), after drug withdraw, either replated for colony formation assay (n = 3 independent experiments) (G) or incubated with EdU for 10 h, and stained at 8 dpt (n = 9 samples from 3 independent experiments) (H).ICells were treated with vehicle or abemaciclib (250 nM or 500 nM or 1 μM for 8 times in 24 h); after drug withdraw, the cells were replated for colony formation assay (n = 3 independent experiments).JRepresentative phase‐contrast images of BJ or WI38 cells at the end of each drug treatment (scale bar, 1 mm; n = 3 independent experiments).KAt 8 dpt, treated BJ cells were fixed and stained for SA‐β‐gal and quantified (scale bar, 1 mm; n = 3 independent experiments).LWhole‐cell lysate of treated BJ cells was used to immunoblot for p16 (n = 3 independent experiments).M–ORNA‐sequencing was performed with human fibroblasts (BJ) treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h) (n = 3 independent samples, sequenced together). Heatmap of cell cycle genes (M), senescence signature (N), and p53‐repressed (red) and p53‐activated (blue) cell cycle‐related genes (O) calculated from RNA‐seq datasets of cells 8 dpt relative to the vehicle‐treated group.PCells were treated with vehicle or abemaciclib (1 μM for 8 times in 24 h); after drug withdraw, the nuclear fraction was isolated and protein extracted for Western blotting. Lamin A/C was used as the marker of nucleus and loading control (n = 3 independent experiments). Data information: Data are means ± SD. Two‐way ANOVA (B, C, and H). One‐way ANOVA (D, E, and K). ***P < 0.001.CC BY · PubMed Central
Figure 1 CDK4/6i treatment induces a state of cellular senescence dependent on p53 activity A, BHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). The population doubling over the 8‐day treatment is plotted (A). 1 or 8 dpt, cells were incubated with EdU for 20 h and stained and quantified (n = 9 samples from 3 independent experiments; scale bar, 150 μm) (B).CChromatin was extracted from BJ cells treated with vehicle or abemaciclib (1 μM for 8 times in 24 h) or nutlin‐3a (10 μM for 8 times in 24 h) or doxorubicin (250 nM for 24 h), and ChIP assays using an antibody against p53 were performed. qRT–PCR was performed using primers amplifying promoter regions of CDKN1A, GADD45A, and MDM2 genes containing p53 binding sites. Values indicate fold enrichment relative to the vehicle group (n = 3 independent experiments).DBJ cells transduced with a p53 reporter were treated with nutlin‐3a (10 μM, positive control) or abemaciclib (1 μM for 1 or 4 or 8 times in 24 h), and luciferase activity was measured after treatments at the indicated time points (n = 3 independent experiments).E3 × 103 BJ cells of the indicated genotypes were replated after vehicle or abemaciclib treatment (1 μM) and stained with 0.2% crystal violet 8 dpt (n = 3 independent experiments).F8 dpt, treated BJ cells were incubated with EdU for 20 h and stained (n = 9 samples from 3 independent experiments).G3 × 103 mouse dermal fibroblasts (MDFs) of the indicated genotypes were replated after vehicle or abemaciclib treatment (4 μM for 8 times in 24 h) and stained with 0.2% crystal violet 8 dpt (n = 3 independent experiments).H8 dpt, treated MDFs were incubated with EdU for 20 h and stained (n = 9 samples from 3 independent experiments).IRNA was isolated from vehicle‐ or abemaciclib (1 μM)‐treated scramble/shp53 BJ cells, and mRNA for the indicated genes was quantified by qRT–PCR relative to tubulin (n = 3 independent experiments). Data information: Data are means ± SD. Unpaired Student’s t‐test (A and H). One‐way ANOVA (B, D, and F). Two‐way ANOVA (C and I). *P < 0.05, **P < 0.01, and ***P < 0.001. dpt, days post‐treatment.
Figure 1 CDK4/6i treatment induces a state of cellular senescence dependent on p53 activity A, BHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). The population doubling over the 8‐day treatment is plotted (A). 1 or 8 dpt, cells were incubated with EdU for 20 h and stained and quantified (n = 9 samples from 3 independent experiments; scale bar, 150 μm) (B).CChromatin was extracted from BJ cells treated with vehicle or abemaciclib (1 μM for 8 times in 24 h) or nutlin‐3a (10 μM for 8 times in 24 h) or doxorubicin (250 nM for 24 h), and ChIP assays using an antibody against p53 were performed. qRT–PCR was performed using primers amplifying promoter regions of CDKN1A, GADD45A, and MDM2 genes containing p53 binding sites. Values indicate fold enrichment relative to the vehicle group (n = 3 independent experiments).DBJ cells transduced with a p53 reporter were treated with nutlin‐3a (10 μM, positive control) or abemaciclib (1 μM for 1 or 4 or 8 times in 24 h), and luciferase activity was measured after treatments at the indicated time points (n = 3 independent experiments).E3 × 103 BJ cells of the indicated genotypes were replated after vehicle or abemaciclib treatment (1 μM) and stained with 0.2% crystal violet 8 dpt (n = 3 independent experiments).F8 dpt, treated BJ cells were incubated with EdU for 20 h and stained (n = 9 samples from 3 independent experiments).G3 × 103 mouse dermal fibroblasts (MDFs) of the indicated genotypes were replated after vehicle or abemaciclib treatment (4 μM for 8 times in 24 h) and stained with 0.2% crystal violet 8 dpt (n = 3 independent experiments).H8 dpt, treated MDFs were incubated with EdU for 20 h and stained (n = 9 samples from 3 independent experiments).IRNA was isolated from vehicle‐ or abemaciclib (1 μM)‐treated scramble/shp53 BJ cells, and mRNA for the indicated genes was quantified by qRT–PCR relative to tubulin (n = 3 independent experiments). Data information: Data are means ± SD. Unpaired Student’s t‐test (A and H). One‐way ANOVA (B, D, and F). Two‐way ANOVA (C and I). *P < 0.05, **P < 0.01, and ***P < 0.001. dpt, days post‐treatment.CC BY · PubMed Central
Figure EV2 CDK4/6i induces cellular senescence dependent on p53 Immunoblot of p53 on cells of indicated genotypes and treatments.Representative images of p53GSE BJ cells at the end of the 8‐day indicated treatments (scale bar, 1 mm; n = 3 independent experiments).8‐day population doubling of treated p53GSE BJ cells (n = 3 independent experiments).3 × 103 vehicle or palbociclib‐treated (1 μM for 8 times in 24 h) scramble/shp53/ p53GSE BJ cells were replated in 6‐well dishes, cultured for 8 days, and stained with 0.2% crystal violet (n = 3 independent experiments).3 × 103 vehicle‐ or abemaciclib‐treated (4 μM for 8 times in 24 h) WT/p53GSE MEFs were replated in 6‐well dishes, cultured for 8 days and stained with 0.2% crystal violet (n = 3 independent experiments).BJ cells were treated with abemaciclib ± pifithrin‐α and EdU staining performed at 8 dpt (n = 9 samples from 3 independent experiments). Data information: Data are means ± SD. One‐way ANOVA (C). Unpaired two‐tailed t‐test (F). ***P < 0.001.
Figure EV2 CDK4/6i induces cellular senescence dependent on p53 Immunoblot of p53 on cells of indicated genotypes and treatments.Representative images of p53GSE BJ cells at the end of the 8‐day indicated treatments (scale bar, 1 mm; n = 3 independent experiments).8‐day population doubling of treated p53GSE BJ cells (n = 3 independent experiments).3 × 103 vehicle or palbociclib‐treated (1 μM for 8 times in 24 h) scramble/shp53/ p53GSE BJ cells were replated in 6‐well dishes, cultured for 8 days, and stained with 0.2% crystal violet (n = 3 independent experiments).3 × 103 vehicle‐ or abemaciclib‐treated (4 μM for 8 times in 24 h) WT/p53GSE MEFs were replated in 6‐well dishes, cultured for 8 days and stained with 0.2% crystal violet (n = 3 independent experiments).BJ cells were treated with abemaciclib ± pifithrin‐α and EdU staining performed at 8 dpt (n = 9 samples from 3 independent experiments). Data information: Data are means ± SD. One‐way ANOVA (C). Unpaired two‐tailed t‐test (F). ***P < 0.001.CC BY · PubMed Central
Figure EV3 Senescence‐inducing dose of abemaciclib inhibits tumor growth Scheme of abemaciclib treatments for MMTV‐PyMT‐firefly breast cancer mouse model in vivo.Female p16‐3MR mice bearing MMTV‐PyMT‐firefly tumors in mammary fat pad were treated with vehicle (PBS, 7 consecutive days) or abemaciclib (50 mg/kg in PBS, 7 consecutive days). The mice were injected with D‐Luciferin, and bioluminescence was visualized/quantified by the IVIS spectrum in vivo imaging system before and after abemaciclib treatments, as shown by representative images and quantification (n = 5 mice/group).Excised tumors and quantification of tumor weights (n = 5 mice/group). Data information: Data are means ± SD. Unpaired two‐tailed t‐test (B and C). *P < 0.05 and **P < 0.01.
Figure EV3 Senescence‐inducing dose of abemaciclib inhibits tumor growth Scheme of abemaciclib treatments for MMTV‐PyMT‐firefly breast cancer mouse model in vivo.Female p16‐3MR mice bearing MMTV‐PyMT‐firefly tumors in mammary fat pad were treated with vehicle (PBS, 7 consecutive days) or abemaciclib (50 mg/kg in PBS, 7 consecutive days). The mice were injected with D‐Luciferin, and bioluminescence was visualized/quantified by the IVIS spectrum in vivo imaging system before and after abemaciclib treatments, as shown by representative images and quantification (n = 5 mice/group).Excised tumors and quantification of tumor weights (n = 5 mice/group). Data information: Data are means ± SD. Unpaired two‐tailed t‐test (B and C). *P < 0.05 and **P < 0.01.CC BY · PubMed Central
Figure 2 CDK4/6i promotes premature senescent cells in vivo without toxicity A–Ep16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). n = 6 mice/group. 14 dpt, bioluminescence was visualized and quantified by the IVIS spectrum in vivo imaging system, as shown by representative bioluminescence images (A) and quantification (B). RNA was isolated from kidneys, and mRNA encoding p16 was quantified by qRT–PCR (C). Representative images (D) to visualize SA‐β‐gal activities in vehicle‐, doxorubicin‐, or abemaciclib‐treated mouse kidney sections at 15 dpt (arrows indicated positive area; scale bar, 1 mm; n = 3 mice/group) and quantified (E).Fp16‐3MR mice were treated with abemaciclib (50 mg/kg, 7 consecutive days) ± pifithrin‐α (2 mg/kg, 7 consecutive days). Values indicate the ratio of post‐treatment bioluminescence to pretreatment (n = 5 mice/group).GRNA was isolated from abemaciclib ± pifithrin‐α treated kidneys, and mRNA encoding p16 and p21 genes was quantified by qRT–PCR and normalized on tubulin (n = 5 mice/group).H–NFor the doxorubicin‐ or abemaciclib‐treated mice (n = 6 mice/group), physical performance was measured by rotarod assay at 15 dpt (H), and grip strength meter at 7 dpt and 14 dpt (I), and hanging tests were performed at 7 dpt and 14 dpt and normalized to weights (J). (K) Relative weight changes were calculated at 7 dpt and 14 dpt. Red blood cells (L) and white blood cells (M) were counted at 15 dpt. Percentage of T cells, B cells, granulocytes, and macrophages were determined by flow cytometry analysis (N). Data information: Data are means ± SD. One‐way ANOVA (B, C, E, H, L, and M). Unpaired Student’s t‐test. (F). Two‐way ANOVA (G, I, J, K, and N). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. dpt, days post‐treatment.
Figure 2 CDK4/6i promotes premature senescent cells in vivo without toxicity A–Ep16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). n = 6 mice/group. 14 dpt, bioluminescence was visualized and quantified by the IVIS spectrum in vivo imaging system, as shown by representative bioluminescence images (A) and quantification (B). RNA was isolated from kidneys, and mRNA encoding p16 was quantified by qRT–PCR (C). Representative images (D) to visualize SA‐β‐gal activities in vehicle‐, doxorubicin‐, or abemaciclib‐treated mouse kidney sections at 15 dpt (arrows indicated positive area; scale bar, 1 mm; n = 3 mice/group) and quantified (E).Fp16‐3MR mice were treated with abemaciclib (50 mg/kg, 7 consecutive days) ± pifithrin‐α (2 mg/kg, 7 consecutive days). Values indicate the ratio of post‐treatment bioluminescence to pretreatment (n = 5 mice/group).GRNA was isolated from abemaciclib ± pifithrin‐α treated kidneys, and mRNA encoding p16 and p21 genes was quantified by qRT–PCR and normalized on tubulin (n = 5 mice/group).H–NFor the doxorubicin‐ or abemaciclib‐treated mice (n = 6 mice/group), physical performance was measured by rotarod assay at 15 dpt (H), and grip strength meter at 7 dpt and 14 dpt (I), and hanging tests were performed at 7 dpt and 14 dpt and normalized to weights (J). (K) Relative weight changes were calculated at 7 dpt and 14 dpt. Red blood cells (L) and white blood cells (M) were counted at 15 dpt. Percentage of T cells, B cells, granulocytes, and macrophages were determined by flow cytometry analysis (N). Data information: Data are means ± SD. One‐way ANOVA (B, C, E, H, L, and M). Unpaired Student’s t‐test. (F). Two‐way ANOVA (G, I, J, K, and N). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. dpt, days post‐treatment.CC BY · PubMed Central
Figure EV4 CDK4/6i induces cellular senescence without pro‐inflammatory SASP BJ cells were treated with vehicle or abemaciclib and stained for mitochondria ROS. Relative values of ROS level were plotted (n = 4 independent experiments).Human hTERT‐RPE1 and lung mesenchymal stem cells were treated with vehicle (DMSO for 8 times in 24 h) or doxorubicin (250 nM for 24 h) or paclitaxel (50 nM for 24 h) or palbociclib (1 μM for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). At 8 dpt, treated cells were fixed and stained for SA‐β‐gal (scale bar, 1 mm; n = 3 independent experiments).At 8 dpt, RNA was isolated from treated cells and indicated NF‐κB‐associated SASP (NASP) genes were quantified by qRT–PCR relative to tubulin (n = 3 independent experiments).qRT–PCR of indicated genes was performed using mouse embryonic fibroblast (MEFs) 8 days after the indicated treatments (n = 3 independent experiments).RFP+ cells were sorted from renal cortex of doxorubicin‐ or abemaciclib‐treated p16‐3MR mice. The percentage of RFP+ cells in total cells was plotted (n = 4 mice/group). Data information: Data are means ± SD. Two‐way ANOVA (C and D). One‐way ANOVA (E). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant.
Figure EV4 CDK4/6i induces cellular senescence without pro‐inflammatory SASP BJ cells were treated with vehicle or abemaciclib and stained for mitochondria ROS. Relative values of ROS level were plotted (n = 4 independent experiments).Human hTERT‐RPE1 and lung mesenchymal stem cells were treated with vehicle (DMSO for 8 times in 24 h) or doxorubicin (250 nM for 24 h) or paclitaxel (50 nM for 24 h) or palbociclib (1 μM for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). At 8 dpt, treated cells were fixed and stained for SA‐β‐gal (scale bar, 1 mm; n = 3 independent experiments).At 8 dpt, RNA was isolated from treated cells and indicated NF‐κB‐associated SASP (NASP) genes were quantified by qRT–PCR relative to tubulin (n = 3 independent experiments).qRT–PCR of indicated genes was performed using mouse embryonic fibroblast (MEFs) 8 days after the indicated treatments (n = 3 independent experiments).RFP+ cells were sorted from renal cortex of doxorubicin‐ or abemaciclib‐treated p16‐3MR mice. The percentage of RFP+ cells in total cells was plotted (n = 4 mice/group). Data information: Data are means ± SD. Two‐way ANOVA (C and D). One‐way ANOVA (E). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant.CC BY · PubMed Central
Figure 3 CDK4/6i‐induced senescence lacks NF‐κB activity and NF‐κB‐driven SASP components A8 dpt, cells were stained for γ‐H2AX (scale bar, 60 μm) and quantified (vehicle = 288 cells, doxorubicin = 280 cells, palbociclib = 276 cells, abemaciclib = 266 cells from 3 independent experiments).BBJ cells transduced with a NF‐κB reporter were treated with vehicle, doxorubicin, paclitaxel (50 nM for 24 h), palbociclib (1 μM for 8 times in 24 h), or abemaciclib, and luciferase activity was measured 8 dpt. TNF‐α treatment was used as positive control (n = 3 independent experiments).C, DVenn plot of RNA‐sequencing datasets of treated cells at 8 dpt (n = 3 independent samples, sequenced together) (C). Heatmap of the SASP genes (D) (Table EV2) for doxorubicin‐ or abemaciclib‐treated groups (8 dpt) relative to the vehicle‐treated group from the RNA‐sequencing datasets (P < 0.01 was regarded as significant).E8 dpt, qRT–PCR of indicated NF‐κB‐associated SASP genes was performed using indicated treated BJ cells 8 dpt (n = 3 independent experiments).FSerum‐free conditioned media (CM) were collected from vehicle‐, doxorubicin‐, paclitaxel‐, palbociclib‐, or abemaciclib‐treated BJ cells 8 dpt, and expression levels of CXCL1 and CCL5 were measured by ELISA (n = 6 independent experiments).GProteins in the serum‐free conditioned media (CM) collected from doxorubicin‐ or abemaciclib‐treated BJ fibroblasts (8 dpt) were measured by cytokine array. Purple boxes indicated internal positive controls from each membrane; red boxes highlighted the most typical SASP factors.H–Kp16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). 15 dpt, plasma was collected and expression levels of CXCL1 were measured by ELISA (H); protein lysate was obtained from drug‐treated kidneys to quantify IL‐6 by ELISA (I); and RNA was isolated from kidneys, and mRNA encoding indicated NF‐κB‐associated genes (J) were quantified by qRT–PCR. n = 6 mice/group. From a subset of the mice, RFP+ cells were sorted from the renal cortex using FACS and mRNA encoding indicated NF‐κB‐associated pro‐inflammatory genes were quantified by qRT–PCR. The values of fold change over vehicle were plotted in the heatmap. n = 4 mice/group (K).LCell‐free plasma was derived from breast cancer patients treated with paclitaxel (n = 10) or palbociclib (n = 9) and the expression levels of CXCL1, CCL2, CCL5, and MMP1 were quantified by ELISA. The values represent the ratio between on‐treatment and pretreatment levels for each patient. Data information: Data are means ± SD. One‐way ANOVA (A, B, F, H and I). Two‐way ANOVA (E and J). Unpaired Student’s t‐test (L). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. Doxo, doxorubicin. Abe, abemaciclib. dpt, days post‐treatment.
Figure 3 CDK4/6i‐induced senescence lacks NF‐κB activity and NF‐κB‐driven SASP components A8 dpt, cells were stained for γ‐H2AX (scale bar, 60 μm) and quantified (vehicle = 288 cells, doxorubicin = 280 cells, palbociclib = 276 cells, abemaciclib = 266 cells from 3 independent experiments).BBJ cells transduced with a NF‐κB reporter were treated with vehicle, doxorubicin, paclitaxel (50 nM for 24 h), palbociclib (1 μM for 8 times in 24 h), or abemaciclib, and luciferase activity was measured 8 dpt. TNF‐α treatment was used as positive control (n = 3 independent experiments).C, DVenn plot of RNA‐sequencing datasets of treated cells at 8 dpt (n = 3 independent samples, sequenced together) (C). Heatmap of the SASP genes (D) (Table EV2) for doxorubicin‐ or abemaciclib‐treated groups (8 dpt) relative to the vehicle‐treated group from the RNA‐sequencing datasets (P < 0.01 was regarded as significant).E8 dpt, qRT–PCR of indicated NF‐κB‐associated SASP genes was performed using indicated treated BJ cells 8 dpt (n = 3 independent experiments).FSerum‐free conditioned media (CM) were collected from vehicle‐, doxorubicin‐, paclitaxel‐, palbociclib‐, or abemaciclib‐treated BJ cells 8 dpt, and expression levels of CXCL1 and CCL5 were measured by ELISA (n = 6 independent experiments).GProteins in the serum‐free conditioned media (CM) collected from doxorubicin‐ or abemaciclib‐treated BJ fibroblasts (8 dpt) were measured by cytokine array. Purple boxes indicated internal positive controls from each membrane; red boxes highlighted the most typical SASP factors.H–Kp16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). 15 dpt, plasma was collected and expression levels of CXCL1 were measured by ELISA (H); protein lysate was obtained from drug‐treated kidneys to quantify IL‐6 by ELISA (I); and RNA was isolated from kidneys, and mRNA encoding indicated NF‐κB‐associated genes (J) were quantified by qRT–PCR. n = 6 mice/group. From a subset of the mice, RFP+ cells were sorted from the renal cortex using FACS and mRNA encoding indicated NF‐κB‐associated pro‐inflammatory genes were quantified by qRT–PCR. The values of fold change over vehicle were plotted in the heatmap. n = 4 mice/group (K).LCell‐free plasma was derived from breast cancer patients treated with paclitaxel (n = 10) or palbociclib (n = 9) and the expression levels of CXCL1, CCL2, CCL5, and MMP1 were quantified by ELISA. The values represent the ratio between on‐treatment and pretreatment levels for each patient. Data information: Data are means ± SD. One‐way ANOVA (A, B, F, H and I). Two‐way ANOVA (E and J). Unpaired Student’s t‐test (L). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. Doxo, doxorubicin. Abe, abemaciclib. dpt, days post‐treatment.CC BY · PubMed Central
Figure 4 p53‐associated SASP factors are induced during CDK4/6i‐induced senescence AHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h), abemaciclib (1 μM for 8 times in 24 h), or doxorubicin (250 nM for 24 h). RNA‐sequencing was performed with treated cells at 8 dpt (n = 3 independent samples, sequenced together) and heatmap of the p53‐associated SASP for doxorubicin‐ or abemaciclib‐treated groups (8 dpt) relative to vehicle‐treated group from the RNA‐sequencing datasets (P < 0.01 was regarded as significant).BHuman BJ fibroblasts, hTERT‐RPE1 epithelial cells, and lung mesenchymal stem cells were treated with vehicle (DMSO for 8 times in 24 h) or doxorubicin (250 nM for 24 h) or paclitaxel (50 nM for 24 h) or palbociclib (1 μM for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). At 8 dpt, RNA was isolated and mRNA for the indicated p53‐associated SASP genes was quantified by qRT–PCR relative to tubulin (n = 3 independent experiments).CChromatin was extracted from BJ fibroblasts treated with vehicle or abemaciclib or nutlin‐3a, and ChIP assays using an antibody against p53 were performed. qRT–PCR was performed using primers amplifying the promoter region of IGFBP3 containing p53 binding sites. Values indicate fold enrichment relative to the vehicle group (n = 4 independent experiments).D, ERNA was isolated from vehicle‐, abemaciclib (1 μM)‐ (D), or palbociclib (1 μM) (E)‐treated scramble/shp53 BJ cells and quantified by qRT–PCR for IGFBP3 or LIF genes (n = 3 independent experiments).FRNA was isolated from kidneys treated with doxorubicin or abemaciclib, and mRNA encoding indicated p53‐associated SASP genes were quantified by qRT–PCR (n = 6 mice/group).GRNA was isolated from kidneys of p16‐3MR mice treated with abemaciclib (50 mg/kg, 7 consecutive days) ± pifithrin‐α (2 mg/kg, 7 consecutive days), and mRNA encoding p53‐associated SASP genes were quantified by qRT–PCR and normalized on tubulin (n = 5 mice/group).HCell‐free plasma was derived from breast cancer patients treated with paclitaxel (n = 10) or palbociclib (n = 9), and the expression levels of IGFBP3 were quantified by ELISA. The values represent the ratio between on‐treatment and pretreatment levels for each patient.IRNA was isolated from vehicle‐ or nutlin‐3a (1 μM for 8 times in 24 h)‐treated BJ cells at 8 dpt and quantified by qRT–PCR for p53 target cell cycle genes, SASP genes (n = 3 independent experiments).JMouse dermal fibroblasts (MDF) or MDF‐p53−/− fibroblasts were transfected with empty vector (EV) or p53‐overexpressing vector (p53OE); then, the cells were treated with vehicle (water) or doxorubicin (250 nM for 24 h) and qRT–PCR was performed for Igfbp3 and Lif genes (n = 3 independent experiments). Data information: Data are means ± SD. Two‐way ANOVA (B, D, E, F, G, I, and J). One‐way ANOVA (C). Unpaired Student’s t‐test (H). *P < 0.05, **P < 0.01, and ***P < 0.001. EV, empty vector, dpt, days post‐treatment.
Figure 4 p53‐associated SASP factors are induced during CDK4/6i‐induced senescence AHuman fibroblasts (BJ) were treated with vehicle (water for 8 times in 24 h), abemaciclib (1 μM for 8 times in 24 h), or doxorubicin (250 nM for 24 h). RNA‐sequencing was performed with treated cells at 8 dpt (n = 3 independent samples, sequenced together) and heatmap of the p53‐associated SASP for doxorubicin‐ or abemaciclib‐treated groups (8 dpt) relative to vehicle‐treated group from the RNA‐sequencing datasets (P < 0.01 was regarded as significant).BHuman BJ fibroblasts, hTERT‐RPE1 epithelial cells, and lung mesenchymal stem cells were treated with vehicle (DMSO for 8 times in 24 h) or doxorubicin (250 nM for 24 h) or paclitaxel (50 nM for 24 h) or palbociclib (1 μM for 8 times in 24 h) or abemaciclib (1 μM for 8 times in 24 h). At 8 dpt, RNA was isolated and mRNA for the indicated p53‐associated SASP genes was quantified by qRT–PCR relative to tubulin (n = 3 independent experiments).CChromatin was extracted from BJ fibroblasts treated with vehicle or abemaciclib or nutlin‐3a, and ChIP assays using an antibody against p53 were performed. qRT–PCR was performed using primers amplifying the promoter region of IGFBP3 containing p53 binding sites. Values indicate fold enrichment relative to the vehicle group (n = 4 independent experiments).D, ERNA was isolated from vehicle‐, abemaciclib (1 μM)‐ (D), or palbociclib (1 μM) (E)‐treated scramble/shp53 BJ cells and quantified by qRT–PCR for IGFBP3 or LIF genes (n = 3 independent experiments).FRNA was isolated from kidneys treated with doxorubicin or abemaciclib, and mRNA encoding indicated p53‐associated SASP genes were quantified by qRT–PCR (n = 6 mice/group).GRNA was isolated from kidneys of p16‐3MR mice treated with abemaciclib (50 mg/kg, 7 consecutive days) ± pifithrin‐α (2 mg/kg, 7 consecutive days), and mRNA encoding p53‐associated SASP genes were quantified by qRT–PCR and normalized on tubulin (n = 5 mice/group).HCell‐free plasma was derived from breast cancer patients treated with paclitaxel (n = 10) or palbociclib (n = 9), and the expression levels of IGFBP3 were quantified by ELISA. The values represent the ratio between on‐treatment and pretreatment levels for each patient.IRNA was isolated from vehicle‐ or nutlin‐3a (1 μM for 8 times in 24 h)‐treated BJ cells at 8 dpt and quantified by qRT–PCR for p53 target cell cycle genes, SASP genes (n = 3 independent experiments).JMouse dermal fibroblasts (MDF) or MDF‐p53−/− fibroblasts were transfected with empty vector (EV) or p53‐overexpressing vector (p53OE); then, the cells were treated with vehicle (water) or doxorubicin (250 nM for 24 h) and qRT–PCR was performed for Igfbp3 and Lif genes (n = 3 independent experiments). Data information: Data are means ± SD. Two‐way ANOVA (B, D, E, F, G, I, and J). One‐way ANOVA (C). Unpaired Student’s t‐test (H). *P < 0.05, **P < 0.01, and ***P < 0.001. EV, empty vector, dpt, days post‐treatment.CC BY · PubMed Central
Figure 5 CDK4/6i‐induced senescence lacks pro‐tumorigenic properties but retain ability to promote paracrine senescence and undergo clearance AMCF7 cells were incubated with serum‐free CM collected from treated BJ fibroblasts (8 dpt) containing EdU for 45 h and EdU+ cells quantified (n = 9 samples from 3 independent experiments).BMCF7 cells migrated through the pores of transwell after 24 h of incubation with CM (8 dpt; scale bar, 1 mm; n = 9 samples from 3 independent experiments) were stained with 0.2% crystal violet and quantified.CMigration of A549 cells exposed to CM collected from treated BJ cells (8 dpt; n = 4 independent samples, imaged together) was evaluated using a scratch assay. Imaging and analysis were done using a live imaging system.D, ETreated BJ fibroblasts (2.5*105) were co‐injected with A549 cancer cells (106) subcutaneously in Foxn1Nu mice, tumor growth was measured at the indicated times (n = 6 mice/group) (D), and the excised tumors were weighed (E).F, Gp16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). n = 6 or 7 mice/group. At 14 dpt, MMTV‐PyMT mouse breast cancer cells were implanted in the mammary fat pad of treated female mice. The tumors were excised and weighed 21 days post‐inoculation (left panel, images of the tumors; right panel, tumor weights) (F). The survival curves for different groups were plotted (G).H, I2 × 105 cells of vehicle‐treated (water for 8 times in 24 h) mouse dermal fibroblasts (MDFs) were injected into the left flank of the p16‐3MR mice. Doxorubicin‐induced (250 nM for 24 h) (H) or abemaciclib‐induced (4 μM for 8 times in 24 h) (I) MDFs were injected into the right flank of the same animal. 7 dpt, the above‐mentioned mice were injected with coelenterazine and bioluminescence from the p16‐3MR mouse was visualized/quantified by the IVIS spectrum in vivo imaging system and quantified. Lower panel, scheme of experimental design (n = 4 mice/group).JEqual amount (2 × 105 cells) of doxorubicin‐induced (250 nM for 24 h, right flank) and abemaciclib‐induced (4 μM for 8 times in 24 h, left flank) senescent MDF‐3MR cells was subcutaneously injected into the same wild‐type mice. At 1 dpt, 7 dpt, and 15 dpt, the above‐mentioned mice were injected with coelenterazine and bioluminescence from the injected MDF‐3MR cells was visualized/quantified by the IVIS spectrum in vivo imaging system and quantified (n = 4 mice/group). Upper panel, scheme of experimental design. Data information: Data are means ± SD. One‐way ANOVA (A, B, E, and F). Two‐way ANOVA (C, D and J). Paired Student’s t‐test (H and I). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. dpt, days post‐treatment. PRO, proliferating cells. SEN, senescent cells. CM, conditioned media.
Figure 5 CDK4/6i‐induced senescence lacks pro‐tumorigenic properties but retain ability to promote paracrine senescence and undergo clearance AMCF7 cells were incubated with serum‐free CM collected from treated BJ fibroblasts (8 dpt) containing EdU for 45 h and EdU+ cells quantified (n = 9 samples from 3 independent experiments).BMCF7 cells migrated through the pores of transwell after 24 h of incubation with CM (8 dpt; scale bar, 1 mm; n = 9 samples from 3 independent experiments) were stained with 0.2% crystal violet and quantified.CMigration of A549 cells exposed to CM collected from treated BJ cells (8 dpt; n = 4 independent samples, imaged together) was evaluated using a scratch assay. Imaging and analysis were done using a live imaging system.D, ETreated BJ fibroblasts (2.5*105) were co‐injected with A549 cancer cells (106) subcutaneously in Foxn1Nu mice, tumor growth was measured at the indicated times (n = 6 mice/group) (D), and the excised tumors were weighed (E).F, Gp16‐3MR mice were treated with vehicle (PBS, 7 consecutive days), doxorubicin (5 mg/kg, 3 consecutive days), or abemaciclib (50 mg/kg, 7 consecutive days). n = 6 or 7 mice/group. At 14 dpt, MMTV‐PyMT mouse breast cancer cells were implanted in the mammary fat pad of treated female mice. The tumors were excised and weighed 21 days post‐inoculation (left panel, images of the tumors; right panel, tumor weights) (F). The survival curves for different groups were plotted (G).H, I2 × 105 cells of vehicle‐treated (water for 8 times in 24 h) mouse dermal fibroblasts (MDFs) were injected into the left flank of the p16‐3MR mice. Doxorubicin‐induced (250 nM for 24 h) (H) or abemaciclib‐induced (4 μM for 8 times in 24 h) (I) MDFs were injected into the right flank of the same animal. 7 dpt, the above‐mentioned mice were injected with coelenterazine and bioluminescence from the p16‐3MR mouse was visualized/quantified by the IVIS spectrum in vivo imaging system and quantified. Lower panel, scheme of experimental design (n = 4 mice/group).JEqual amount (2 × 105 cells) of doxorubicin‐induced (250 nM for 24 h, right flank) and abemaciclib‐induced (4 μM for 8 times in 24 h, left flank) senescent MDF‐3MR cells was subcutaneously injected into the same wild‐type mice. At 1 dpt, 7 dpt, and 15 dpt, the above‐mentioned mice were injected with coelenterazine and bioluminescence from the injected MDF‐3MR cells was visualized/quantified by the IVIS spectrum in vivo imaging system and quantified (n = 4 mice/group). Upper panel, scheme of experimental design. Data information: Data are means ± SD. One‐way ANOVA (A, B, E, and F). Two‐way ANOVA (C, D and J). Paired Student’s t‐test (H and I). *P < 0.05, **P < 0.01, and ***P < 0.001, N.S. = not significant. dpt, days post‐treatment. PRO, proliferating cells. SEN, senescent cells. CM, conditioned media.CC BY · PubMed Central
Figure EV5 p53‐associated SASP lacks pro‐tumorigenic properties A549 and HCC827 lung cancer cells were incubated with drug‐induced BJ or WI38 serum‐free CM for 45 h. Cells were replated for colony formation assay for 8 days (n = 3 independent experiments).Excised tumors from Fig 5D (n = 6 mice/group).
Figure EV5 p53‐associated SASP lacks pro‐tumorigenic properties A549 and HCC827 lung cancer cells were incubated with drug‐induced BJ or WI38 serum‐free CM for 45 h. Cells were replated for colony formation assay for 8 days (n = 3 independent experiments).Excised tumors from Fig 5D (n = 6 mice/group).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Laberge R‐M, Sun YU, Orjalo AV, Patil CK, Freund A, Zhou L, Curran S, Davalos AR, Wilson‐Edell KA, Liu SU et al (2015b) MTOR regulates the pro‐tumorigenic senescence‐associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 17: 1049–1061 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M.
Affiliations
  • University Medical Center Groningen (NL)
  • Erasmus MC (NL)
  • Osaka City University (JP)
Corresponding author
Demaria, Marco
Venue
The EMBO Journal
Published
2022-01-05
Volume
41
Issue
6
Pages
e108946-e108946
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W4206812574
Cited by
113
References
54
Citations by year
2026: 27 · 2025: 27 · 2024: 29 · 2023: 18 · 2022: 12
FWCI
13.31
Type
journal article
Language
en
Open access
Licence
Locations
  • The EMBO Journal (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, public-domain)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
KWF Kankerbestrijding (10989)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
cellular senescence, CDK4/6 inhibitors, p53, senescence-associated secretory phenotype, premature senescence, paracrine senescence, NF-κB, breast cancer, drug-induced senescence
MeSH terms
Animals, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Tumor Suppressor Protein p53, NF-kappa B, Cellular Senescence, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity. https://app.cochat.ai/papers/10.15252/embj.2021108946
The paper
Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M. (2022). Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity. The EMBO Journal. https://doi.org/10.15252/embj.2021108946

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.